As a non-profit organization, Brave River Science Foundation allocates 5% of our sponsored research agreements to cover the grantee institution’s indirect costs. This policy is rooted in our dedication to transparency, accountability, and effective use of our funds. By capping indirect costs at 5%, we ensure that every dollar received is maximized for the advancement of our mission of accelerating the development of NF1 therapeutics.